AB-related Paper Published in the American Scientific Journal Science

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that lecanemab, an anti-amyloid-β protofibril antibody being developed by Eisai, has no connection regarding an article published in the US scientific journal Science on July 22, 2022.

This article reported that a research paper on Aβ*56, a type of Aβ oligomer, is under investigation for its credibility, but this case has no relation to lecanemab.

Lecanemab showed a correlation between Aβ removal and a slower clinical decline in Study 201, and the Phase III study Clarity AD is currently underway.

We will continue to make every effort to deliver a new treatment as soon as possible to Alzheimer's disease patients, their families, and medical professionals.

Type Press Release

Date Released July 25, 2022

RECENT RELEASES

Nov 21, 2024

EISAI SUPPORTS SLEEP RESEARCH SOCIETY FOUNDATION EDUCATIONAL WEBINAR: LESSONS LEARNED FROM CENTRAL DISORDERS OF HYPERSOMNOLENCE AND FUTURE DIRECTIONS

Eisai Inc. announced today its sponsorship of the upcoming webinar, "Lessons Learned from Central Disorders of Hypersomnolence and Future Directions", a key educational event from the Sleep...

Nov 14, 2024

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Oct 31, 2024

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...